IPMG seeks to play an important role as a Partner to the HealthCare Stakeholders in improving Indonesia’s healthcare system


IPMG seeks to be the trusted partner to the government of Indonesia and other stakeholders and to play an important role in improving the healthcare system through the core strengths of its members; i.e., medical innovation and manufacturing of products that meet international standards of pharmaceutical quality and safety.


Over the years, pharmaceutical companies have developed countless new drugs to manage diseases and mitigate patient suffering. With the specter of new diseases constantly on the horizon, this commitment to research and development is an ever-present imperative. IPMG members assume such responsibility with passion and commitment.

To ensure fair market practices, IPMG aims to create a favorable business climate, to adhere to existing government laws and regulations, and to uphold our Code of Marketing Practices.


IPMG communicates the role and contribution of R&D-based pharmaceutical manufacturers in helping people improve their quality of life as well as pushing for an advancement of an effective and integrated healthcare system in Indonesia. 

  • Representing the opinions and interests of IPMG members in discussions with the government, regulatory agencies, trade associations, professional associations, and local national pharmaceutical business.
  • To promote and safeguard members’ interests in Indonesia by striving to influence policy developments affecting the health sector.
  • To analyze and interpret the trends and the impacts of changes in legislation relating to the industry.
  • To keep abreast of global developments in pharmaceutical policies through IPMG’s international representation as a member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA).


Established in August 2002, IPMG is a non-profit organization of 25 research-based multinational pharmaceutical companies operating in Indonesia, which is committed to research, development, manufacturing and marketing of high-quality medicines.


To date, IPMG members have introduced more than 900 new products to treat cancer, infectious diseases, cardiovascular diseases and other illnesses in Indonesia.


Member companies employ more than 10,000 people in their operations

Board Of Management

Jorge Wagner
(PT Novartis Indonesia)
Evie Yulin
Vice Chairperson & Head of Market Access Subcommitte
(PT Merck, Tbk.)
Krishnanand Atreya
Honorary Secretary
(PT AstraZeneca Indonesia)
Jude Alexander
Honorary Treasurer
(PT Astellas Pharma Indonesia)
Anil Argilla
Head of Communication Subcommittee
(PT Pfizer Indonesia)
Dr. Ait-Allah Mejri
Head of Government Affairs Subcommittee
(PT Roche Indonesia)
Morten Vaupel
(PT Novo Nordisk Indonesia)
Kwa Kheng Hoe
Head of Medical & Regulatory Subcommittee
(PT Abbott Indonesia)
Angel Michaelo Evangelista
Head of Commercial Excellence & Ethical Practice Subcommittee
(PT Bayer Indonesia)

Board Of Supervisors

Erum S. Rahim
(PT GlaxoSmithKline Pharma Indonesia)

Joselito Sta Ana
(PT Sanofi Indonesia)
George Zaki
(PT Merck Sharp & Dohme Indonesia)

Board Of Secretariat

Mr. Parulian Simanjuntak
Executive Director

Reinelda Reveisionery
Communication Manager
Suyanthy Zoelkifli
Communication Manager
Jony DOminggus